Therapeutic targeting of PP2A

Int J Biochem Cell Biol. 2018 Mar;96:182-193. doi: 10.1016/j.biocel.2017.10.008. Epub 2017 Oct 26.

Abstract

Protein phosphatase 2A (PP2A) is a major serine/threonine phosphatase that regulates many cellular processes. Given the central role of PP2A in regulating diverse biological functions and its dysregulation in many diseases, including cancer, PP2A directed therapeutics have become of great interest. The main approaches leveraged thus far can be categorized as follows: 1) inhibiting endogenous inhibitors of PP2A, 2) targeted disruption of post translational modifications on PP2A subunits, or 3) direct targeting of PP2A. Additional insight into the structural, molecular, and biological framework driving the efficacy of these therapeutic strategies will provide a foundation for the refinement and development of novel and clinically tractable PP2A targeted therapies.

Keywords: ABL-127; Bortezomib; CIP2A; Cancer; Celastrol; Cell signaling; Drug development; Erlotinib; FTY720; LB-100; LCMT-1; OP449; PME-1; PP2A; Phenothiazines; Protein phosphatase 2A; Protein phosphatases; SET; SMAPs; Tumor suppressors.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents* / chemistry
  • Antineoplastic Agents* / therapeutic use
  • Drug Delivery Systems / methods*
  • Enzyme Inhibitors* / chemistry
  • Enzyme Inhibitors* / therapeutic use
  • Humans
  • Neoplasm Proteins* / antagonists & inhibitors
  • Neoplasm Proteins* / genetics
  • Neoplasm Proteins* / metabolism
  • Neoplasms* / drug therapy
  • Neoplasms* / enzymology
  • Neoplasms* / genetics
  • Protein Phosphatase 2* / antagonists & inhibitors
  • Protein Phosphatase 2* / genetics
  • Protein Phosphatase 2* / metabolism
  • Protein Processing, Post-Translational / drug effects

Substances

  • Antineoplastic Agents
  • Enzyme Inhibitors
  • Neoplasm Proteins
  • Protein Phosphatase 2